Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U.S. payer perspective.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Med Econ

Title: Journal of medical economics

Publisher: Informa Healthcare

ISSN (Electronic): 1941-837X

ISSN (Print): 1369-6998

Publication date (Electronic): 2016

Volume: 19

Issue: 3

Affiliations

[1 ] a a Levine Cancer Institute/Carolinas Healthcare System , Charlotte, NC , USA.

[2 ] b b St. Bartholomew's Hospital , West Smithfield, London , UK.

[3 ] c c Cross Cancer Institute , University of Alberta , Edmonton, AB , Canada.

[4 ] d d Bordeaux Hospital University Center (CHU) , Bordeaux , France.

[5 ] e e Royal Wolverhampton Hospitals NHS Trust , Wolverhampton , UK.

[6 ] f f Dalhousie University and QEII Health Sciences Center , Halifax, NS , Canada.

[7 ] g g Winship Cancer Institute , Emory University , Atlanta , GA , USA.

[8 ] h h Celgene Corporation , Summit, NJ , USA.

[9 ] i i Evidera , Lexington, MA , USA.

[10 ] j j Service des Maladies du Sang , Hôpital Huriez , CHRU Lille, Lille , France.

Article

DOI: 10.3111/13696998.2015.1115407

PubMed ID: 26517601

SO-VID: 1cdf6325-1dba-44a2-8a2b-75b883aed80b

History

Keywords: Bortezomib,Cost-benefit analysis,Cost-effectiveness,Drug therapy,Lenalidomide,Multiple myeloma

Data availability:

Keywords: Bortezomib, Cost-benefit analysis, Cost-effectiveness, Drug therapy, Lenalidomide, Multiple myeloma

Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.

Read this article at

Abstract

Related collections

Point-of-Care Testing for Infectious Diseases Super Collection

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 19

Cited by 6